CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
about
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
CCI-779 (Temsirolimus) exhibit ...... ance to cisplatin or cetuximab
@en
type
label
CCI-779 (Temsirolimus) exhibit ...... ance to cisplatin or cetuximab
@en
prefLabel
CCI-779 (Temsirolimus) exhibit ...... ance to cisplatin or cetuximab
@en
P2093
P2860
P1476
CCI-779 (Temsirolimus) exhibit ...... ance to cisplatin or cetuximab
@en
P2093
Albrecht Stenzinger
Franziska Niehr
Ingeborg Tinhofer
Volker Budach
P2860
P2888
P356
10.1186/S12967-015-0456-6
P577
2015-04-01T00:00:00Z
P5875
P6179
1009671977